All rights reserved.) The European Commission (EC) has granted marketing authorisation for AbbVie’s Tepkinly (epcoritamab) in ...
Zacks Investment Research on MSN
EU approves expanded use of ABBV's Tepkinly in follicular lymphoma
AbbVie ABBV announced that the European Commission (EC) approved the expanded use of Tepkinly (epcoritamab) for the relapsed ...
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the ...
The European Commission has authorized a label expansion for Tepkinly, a blood cancer therapy jointly developed by AbbVie (ABBV) and Genmab (GMAB) as a first-line option for patients with follicular ...
AbbVie (ABBV) is back in focus after the European Commission granted marketing authorization for Tepkinly plus lenalidomide ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved to treat both R/R FL and R/R diffuse large B-cell lymphoma (DLBCL) in the European Union (EU), as well as the ...
AbbVie’s CD20xCD3 bispecific antibody Tepkinly has been recommended by NICE for NHS use as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive and fast-growing ...
Genmab A/S(Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY ® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R 2 ) ...
“Follicular lymphoma can be challenging to treat and today's approval of TEPKINLY for the treatment of relapsed/refractory follicular lymphoma after two or more lines of systemic therapy marks an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results